Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-Line Sunitinib (QUASAR): Results of a Phase I Trial.

Front Pharmacol · 2018 · PMC5864863 · PMID 29615901

Europe PMC DOI

hedged sentence

0.0690

closest p · 1.4× alpha

0.0690

boldest claim

The sentences

borderline significantp = 0.069so close (0.05 < p ≤ 0.1)

A borderline significant improvement in quality of life score (5.5 points; 95% CI: −0.1 to 11.1; p = 0.069) was also obtained (see Figures 1 – 3 and Table 5 ).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.